Document is current
Any future updates will be listed below
-
Authors
Qin, Le
Zhao, Ruocong
Chen, Dongmei
Wei, Xinru
Wu, Qiting
Long, Youguo
Jiang, Zhiwu
Li, Yangqiu
Wu, Haipeng
Zhang, Xuchao
Wu, Yilong
Cui, Shuzhong
Wei, Wei
Yao, Huihui
Liu, Zixia
Cao, Su
Yao, Yao
Zhang, Zhenfeng
-
Funding
Funding for this research was provided by:
Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12050305, XDB19030205)
National Natural Science Foundation of China (81961128003, 81972672, 81773301)
National key research and development plan (2017YFE0131600)
The National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2018ZX090201002-005)
Guangdong Provincial Significant New Drugs Development (2019B020202003)
Guangdong Special Support Program (2017TX04R102)
Guangdong Basic and Applied Basic Research Foundation (2017A030310381, 2019A1515010062)
Guangzhou Science and Technology Plan Project (201907010042, 201904010473)
Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR110105003)
Science and Technology Planning Project of Guangdong Province, China (2017B030314056)
- License Information
-
More Information
Article History
Received: 24 April 2020
Accepted: 17 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: All in vitro experimental protocols were performed in accordance with instruction guidelines from the China Council on Animal Care and approved by the guidelines of the Ethics Committee of Animal Experiments at Guangzhou Institutes of Biomedicine and Health (GIBH). Human PBMCs from healthy donors were obtained with informed consent for research purposes, and the procedures were approved by the Research Ethics Board of GIBH. Consent to publish has been obtained from the participant to report individual patient data.
: Consent to publish has been obtained from the participants.
: The authors declare no competing financial interests.
